The use of halogenated thymidine analogs as clinical radiosensitizers: Rationale, current status, and future prospects: Non-hypoxic cell sensitizers
- 1 August 1984
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 10 (8), 1399-1406
- https://doi.org/10.1016/0360-3016(84)90357-2
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Monoclonal Antibody to 5-Bromo- and 5-Iododeoxyuridine: A New Reagent for Detection of DNA ReplicationScience, 1982
- Long-term intraarterial chemotherapy infusion of ambulatory head and neck cancer patientsJournal of Surgical Oncology, 1982
- Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routesClinical Pharmacology & Therapeutics, 1980
- High‐dose intravenous and hepatic artery infusions of thymidineClinical Pharmacology & Therapeutics, 1978
- Radiation Sensitivity of Cultured Human Glioblastoma CellsRadiology, 1977
- Comparison of Intravenous and Intra-arterial Pyrimidine Infusion as a Means of Radiosensitizing TumorsIn VivoRadiology, 1977
- Failure of High Dose 5-Iodo-2′-Deoxyuridine in the Therapy of Herpes Simplex Virus EncephalitisNew England Journal of Medicine, 1975
- Radiosensitization of Malignant Brain Tumours with Bromouridine (Thymidine Analogue)Acta Radiologica: Therapy, Physics, Biology, 1969
- Continuous Irradiation of P388F Lymphomain VitroSensitization by 5-iodo-2′-deoxyuridineInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1967
- GENETICS OF HUMAN CELL LINESThe Journal of Experimental Medicine, 1960